US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

27.45

+0.44001.63%

Post-market: 27.01-0.4400-1.60%16:10 EDT

Volume:98

Turnover:3K

Market Cap:2.47M

PE:- -

High:27.45

Open:27.01

Low:27.45

Close:27.01

52wk High:28.62

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:0.15

T/O Rate:0.11%

Dividend:0.45

Dividend Rate:1.65%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Press Release: Medidata Expands Executive Leadership Team to Scale Operations and Accelerate Growth for Customers

Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Press Release: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b Plateau Clinical Trial Progress

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Press Release: Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

Press Release: Cryoport Reports Second Quarter 2026 Financial Results

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading

MT Newswires Live

Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call

Press Release: Edgewise Therapeutics Reports Second Quarter 2026 Financial Results

Takeda Wins First-in-Class U.S. Approval for Orexin Therapy in Narcolepsy Type 1

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Corbus reports last patient completes last visit in CANYON-1 trial

IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026

Fresenius announces FDA approval of rituximab biosimilar

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

Xencor’s XmAb412 Enters First-in-Human Testing: What Early-Stage Investors Should Watch

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/NVIB/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":27.4504,"timestamp":1788206400000,"preClose":27.0104,"halted":0,"volume":98,"hourTrading":{"tag":"盘后","latestPrice":27.0104,"preClose":27.4504,"latestTime":"16:10 EDT","volume":6,"amount":164.7024,"timestamp":1788207004534,"change":-0.44,"changeRate":-0.016029,"amplitude":0},"delay":0,"changeRate":0.01629002162130134,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Closed","change":0.44,"latestTime":"08-31 16:00:00 EDT","open":27.0104,"high":27.4504,"low":27.4504,"amount":2673,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788249600000},"marketStatusCode":5,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":27.0104,"nav":26.953,"aum":2425792.32,"dividendRate":0.016461,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":27.0104,"preClose":27.4504,"latestTime":"16:10 EDT","volume":6,"amount":164.7024,"timestamp":1788207004534,"change":-0.44,"changeRate":-0.016029,"amplitude":0},"volumeRatio":0.150399},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.150399,"shares":90001,"dividePrice":0.45187,"high":27.4504,"amplitude":0,"preClose":27.0104,"low":27.4504,"week52Low":24.54,"pbRate":"--","week52High":28.621,"institutionHeld":0,"latestPrice":27.4504,"eps":0,"divideRate":0.016461,"volume":98,"delay":0,"ttmEps":0,"open":27.0104,"prevYearClose":25,"prevWeekClose":27.0104,"prevMonthClose":25.6004,"prevQuarterClose":25,"fiveDayClose":25.9412,"twentyDayClose":26.2307},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658193510","title":"Press Release: Medidata Expands Executive Leadership Team to Scale Operations and Accelerate Growth for Customers","url":"https://stock-news.laohu8.com/highlight/detail?id=2658193510","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658193510?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:00","pubTimestamp":1786363200,"startTime":"0","endTime":"0","summary":"NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions, today announced key appointments to its executive leadership team, rei","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DASTY","TISI","BK4120","IDNA","MEDX","HYLG","CUBI","GDOC","BK4023","AAQC","BK4211","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658936984","title":"Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:","url":"https://stock-news.laohu8.com/highlight/detail?id=2658936984","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658936984?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:00","pubTimestamp":1786359600,"startTime":"0","endTime":"0","summary":"Major Regulatory Milestone Positions Company to Initiate Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Patented First-in-Class Neuroprotective Therapy Targeting Demyelination Lucid-MS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341697/0/en/quantum-biopharma-receives-united-states-fda-clearance-to-proceed-with-lucid-ms-phase-2-trial-in-progressive-multiple-sclerosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNTM","BK4007","LU1244550221.USD","BNDI","BK4532","LU2065170008.USD","IND","LCID","PBE","BK4516","LU1481011671.HKD","BK4596","LU2087625088.SGD","IE0004445015.USD","LCIZ","IE00BN29S564.USD","CAGR","LCDL","NBIX","LU0053666078.USD","BIIB","LU1668664300.SGD","BK4099","IE0005OL40V9.USD","LU1035773651.USD","LU1988902786.USD","IAI","LU2089284900.SGD","LU0971096721.USD","IE00B775H168.HKD","LU0772969993.USD","LXRX","BK4139","LU0912757837.SGD","PGR","LU0889565916.HKD","UBCP","LU1718418525.SGD","LABU","LU0070302665.USD","KBWP","BK4504","IAK","NVIB","BMED","IE00BZ1G4Q59.USD","KBWB","LU0320765992.SGD","LU1366192091.USD","LU0731783394.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658369819","title":"Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658369819","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658369819?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:00","pubTimestamp":1786359600,"startTime":"0","endTime":"0","summary":"Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathyPhase 2 JADE101 clinical tria","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341688/0/en/jade-biosciences-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","BK4539","MEDX","BK4139","HYLG","JBIO","NVIB","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658987072","title":"Press Release: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b Plateau Clinical Trial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2658987072","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658987072?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:30","pubTimestamp":1786357800,"startTime":"0","endTime":"0","summary":"-- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients ---- Phase 2b PLATEAU clinical trial interim analysis and r","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","R","BK4097","BK4022","USRD","VERU","BK4007","JDOC","GDOC","LU2065732104.USD","BK4584","BK4557","MEDX","PRGS","NVIB","BK4232","IDNA","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657699541","title":"These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2657699541","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657699541?lang=en_us&edition=fundamental","pubTime":"2026-08-07 13:15","pubTimestamp":1786079700,"startTime":"0","endTime":"0","summary":"Biotech stocks have recaptured investors' attention this year amid a wave of drug innovation, which is spurring merger-and-acquisition activity in the biopharma industry and a fresh round of initial p","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456855351.SGD","LU1934455194.USD","LU0061475181.USD","BBC","LU1037948541.HKD","LU1061106388.HKD","MEDX","GDOC","TRUH","PPH","IE00BJJMRZ35.SGD","RXL","LU0306807586.USD","IE000M9KFDE8.USD","IE00B1BXHZ80.USD","XLV","SG9999001440.SGD","BMY","SG9999014575.USD","BK4578","PBLS","LU2491050154.USD","IXJ","LU2125154778.USD","PAWZ","FHLC","PSIL","LU0965508806.USD","LU0320765489.SGD","LU1941712348.USD","LU1261432733.SGD","VHT","XBI","LU1974910355.USD","JDOC","FTXH","IYH","BMED","LU2461242641.AUD","HRTS","LU1430594728.SGD","IHE","LU2596442595.SGD","MRK","LU0122379950.USD","LU1023059063.AUD","NVIB","LU1929549753.HKD","NVS","LU0980610538.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657419","title":"Press Release: Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657419","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657419?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:08","pubTimestamp":1786046880,"startTime":"0","endTime":"0","summary":"1/2 INSPIRE DUCHENNE clinical trial as of August 4, 2026. Solid plans to. meet with the FDA late in the fourth quarter of 2026 to discuss the. INSPIRE DUCHENNE SGT-003 data package and to seek guidance on a potential","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4588","BK4130","GDOC","IDNA","BK4139","BK4604","BK4555","SLDB","NVIB","TM","MEDX","BK4535","BK4539","FA","HYLG","BK4099","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657945657","title":"Press Release: Cryoport Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657945657","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657945657?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046700,"startTime":"0","endTime":"0","summary":"-- Second quarter revenue grew 8% year-over-year to $49.0 million. -- Life Sciences Services revenue increased 15% year-over-year. -- Supporting 779 global clinical trials and 22 commercially approved cell","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4588","BK4604","MAA","BK4602","BK4099","MEDX","BK4121","BK4555","R","TM","NVIB","GDOC","SPRE","BK4215","CYRX","HYLG","BK4585","BK4022","BK4082","BK4232","IDNA","SCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657661494","title":"Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2657661494","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657661494?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046700,"startTime":"0","endTime":"0","summary":"First patients dosed in aleniglipron (oral small molecule GLP-1 receptor agonist)Phase 3 ACCOMPLISH program for chronic weight management Data from Phase 1 SAD clinical trial of ACCG-2671 (oral small ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/06/3340722/0/en/Structure-Therapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GPCR","LU0823414478.USD","LU2357125470.USD","LENZ","HYLG","IDNA","LU2506951792.HKD","GDOC","BK4139","LU2294711713.HKD","LU2249611893.SGD","BK4539","BK4009","CCO","LU0823414551.USD","NVIB","BMED","BK4599","MEDX","JDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657661430","title":"Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657661430","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657661430?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046700,"startTime":"0","endTime":"0","summary":"Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026 Ini","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/06/3340705/0/en/Trevi-Therapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","LENZ","MEDX","BMED","BK4539","HYLG","BK4007","BK4139","IDNA","GDOC","RCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657653126","title":"European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2657653126","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657653126?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:18","pubTimestamp":1786029491,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were heading higher late Thursday morning, rising 0.85% to 1,947.79 on the S&P Europe Select ADR Index.From continental Europe, the g","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","BK4117","CRTO","MEDI","BK4588","BNTX","CLLS","BK4535","BK4559","IEUR","LU0109394709.USD","BK4551","BK4139","BK4204","BK4023","BBVA","BK4585","IE00BFMHRM44.USD","NVIB","SNN","BK4568","BDRX","MREO","WPP.AU","TRIB","BK4548","DEO","OPRA","PSO","XBIX","BK4009","EPV","WPP","BK4505","AUTL","ASND","BK4077","BK4111","BK4169","BK4207","EVAX","LU0320765992.SGD","BK4107","AFG","LFGY","BK4082","DGE.UK","TRVG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657345566","title":"Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2657345566","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657345566?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:34","pubTimestamp":1786019640,"startTime":"0","endTime":"0","summary":"MINNEAPOLIS, Aug.  06, 2026  (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment o","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/06/3340301/0/en/Celcuity-Schedules-Release-of-Second-Quarter-2026-Financial-Results-and-Webcast-Conference-Call.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","GDOC","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657460636","title":"Press Release: Edgewise Therapeutics Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657460636","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657460636?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017600,"startTime":"0","endTime":"0","summary":"--  Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) ----  Completed sale of sevasemten and musc","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4531","BK4007","IDNA","MEDX","BK4585","BK4588","HYLG","BMED","GDOC","EWTX","HCM","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657572786","title":"Takeda Wins First-in-Class U.S. Approval for Orexin Therapy in Narcolepsy Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2657572786","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657572786?lang=en_us&edition=fundamental","pubTime":"2026-08-06 07:25","pubTimestamp":1785972320,"startTime":"0","endTime":"0","summary":"The latest update is out from Takeda Pharmaceutical Co ( ($JP:4502) ). Takeda has secured U.S. FDA approval for ORZEYFUL, an oral orexin receptor 2...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takeda-wins-first-in-class-u-s-approval-for-orexin-therapy-in-narcolepsy-type-1?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takeda-wins-first-in-class-u-s-approval-for-orexin-therapy-in-narcolepsy-type-1?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PINK","SYNB","MRNX","LFSC","LABU","MRNY","PSCH","FRTY","RSPH","TECB","XLVX","IEIH","NVIB","MEDI","TBXU","IDNA","BBP","BK4585","BK4588","IBB","IYH","BMED","GDOC","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657764305","title":"Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2657764305","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657764305?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:05","pubTimestamp":1785960300,"startTime":"0","endTime":"0","summary":"Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first quarter of 2027Enrollment also ongoing for th","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/05/3339675/0/en/Biomea-Fusion-Reports-Second-Quarter-2026-Financial-Results-and-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","MEDX","HYLG","IDNA","NVIB","BK4585","JDOC","BK4139","GDOC","BMEA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657678575","title":"OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2657678575","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657678575?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:05","pubTimestamp":1785873900,"startTime":"0","endTime":"0","summary":"-- Executing IND-enabling activities for next-generation PI3Kαpan-mutant selective candidates OKI-345 in breast cancer and OKI-355 in vascular anomalies, with IND submissions planned for 1H 2027 -- Ho","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338800/0/en/OnKure-Therapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","MEDX","GDOC","BMED","LENZ","IDNA","BK4139","BK4007","IND","BK4539","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656967554","title":"Corbus reports last patient completes last visit in CANYON-1 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2656967554","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656967554?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:55","pubTimestamp":1785851749,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals (CRBP) announced the last patient has completed their last clinical visit in the company’s CANYON-1 Phase 1b clinical trial ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corbus-reports-last-patient-completes-last-visit-in-canyon-1-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corbus-reports-last-patient-completes-last-visit-in-canyon-1-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRBP","BK4139","GDOC","MEDX","NVIB","IDNA","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656564305","title":"IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2656564305","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656564305?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:00","pubTimestamp":1785844800,"startTime":"0","endTime":"0","summary":"LAWRENCEVILLE, N.J., Aug.  04, 2026  (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338235/0/en/IMUNON-to-Hold-Second-Quarter-2026-Financial-Results-and-Business-Update-Conference-Call-on-Tuesday-August-11-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","NVIB","MEDX","IDNA","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656304376","title":"Fresenius announces FDA approval of rituximab biosimilar","url":"https://stock-news.laohu8.com/highlight/detail?id=2656304376","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656304376?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:15","pubTimestamp":1785788150,"startTime":"0","endTime":"0","summary":"Fresenius Kabi, an operating company of Fresenius (FSNUY), announced that the U.S. Food and Drug Administration has approved a rituximab biosimilar...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fresenius-announces-fda-approval-of-rituximab-biosimilar-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fresenius-announces-fda-approval-of-rituximab-biosimilar-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FSNUY","BMED","FRTY","MEDI","BK4588","LABU","XLVX","IDNA","NVIB","PSCH","BK4196","RSPH","IEIH","TBXU","LFSC","MRNX","IYH","GDOC","BBP","BK4585","TECB","MRNY","SYNB","PINK","IBB","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656078673","title":"ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2656078673","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656078673?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:05","pubTimestamp":1785787500,"startTime":"0","endTime":"0","summary":"Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamid","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/03/3337877/0/en/ORIC-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results-and-Operational-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNGX","IDNA","ORIC","MEDX","HYLG","BK4139","GDOC","AR","BK4213","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656036803","title":"Xencor’s XmAb412 Enters First-in-Human Testing: What Early-Stage Investors Should Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2656036803","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656036803?lang=en_us&edition=fundamental","pubTime":"2026-08-04 00:32","pubTimestamp":1785774763,"startTime":"0","endTime":"0","summary":"Xencor Inc. ($XNCR) announced an update on their ongoing clinical study. Xencor, Inc. is running a Phase 1 clinical trial called “A Phase 1, First-...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xencors-xmab412-enters-first-in-human-testing-what-early-stage-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xencors-xmab412-enters-first-in-human-testing-what-early-stage-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","BK4211","MEDX","GDOC","IDNA","ISBC","BK4139","XNCR","HYLG"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":5,"totalSize":136,"code":"91000000","status":"200"}]}}